Endocrine-responsive breast cancer and strategies for combating resistance.
Deaths from breast cancer have fallen markedly over the past decade due, in part, to the use of endocrine agents that reduce the levels of circulating oestrogens or compete with oestrogen for binding to its receptor. However, many breast tumours either fail to respond or become resistant to endocrine therapies. By understanding the mechanisms that underlie this resistance, we might be able to develop strategies for overcoming or bypassing it.
Ali
Simak
S
Department of Cancer Medicine and Cancer Research Campaign Laboratories, Faculty of Medicine, Imperial College of Science, Technology & Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. simak.ali@ic.ac.uk
Coombes
R Charles
RC
D000818:Animals; D001940:Breast / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D004967:Estrogens / Q000378:metabolism* / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use
D004967:Estrogens; D011960:Receptors, Estrogen; D013629:Tamoxifen